💡 Genezen has experience scaling up and producing LVVs using this system at its GMP vector facility.
🚀 The licensing agreement will help alleviate the global viral vector shortage and provide a high-quality vector platform.
👩🔬 Genezen’s CSO believes that this system will enable customers to reach the clinic faster and produce higher quality LVVs.
💊 CSL’s Cytegrity cell line has been developed over many years and will potentially lower costs and speed up production.
Introduction:
Genezen, a contract development and manufacturing organization (CDMO), has announced that it has licensed CSL’s Cytegrity cell line production system, which is designed for the production of lentiviral vectors (LVVs). This partnership will allow Genezen to scale up and produce LVVs more efficiently, potentially alleviating the global viral vector shortage and accelerating the development of gene therapies.
- Genezen has become the first CDMO to license CSL’s Cytegrity cell line production system for the production of lentiviral vectors (LVVs).
- The use of Cytegrity is expected to help alleviate the global viral vector shortage and provide a scalable and high-quality vector platform for customers.
- Development of stable producer cell lines using Cytegrity can be achieved in under four months, allowing for faster production and lower cost of goods.
- Genezen’s expertise and experience with Cytegrity will enable customers to produce higher quality LVVs at scale and accelerate their journey to the clinic.
- The partnership between Genezen and CSL has the potential to benefit patients by enabling quicker access to gene therapies.
Conclusion:
Genezen’s licensing of CSL’s Cytegrity cell line production system represents a significant development in the field of gene therapy production. By utilizing this system, Genezen aims to address the global viral vector shortage and provide customers with a scalable and high-quality vector platform. The partnership between Genezen and CSL has the potential to accelerate the development and manufacturing of gene therapies, ultimately benefiting patients by providing them with faster access to potentially life-changing treatments.
